FGFR1 and neoplasm: Genomic heterogeneity of copy number alteration in tumour #1 and tumour #2 was observed in 7 (33%) of 21 patients including ERBB2 in two patients (patients 9 and 19), FGFR1 in two patients (patients 3 and 13), and FGFR2 in one patient (patient 4).